Advertisement
There is an association between the presence of abnormally high numbers of circulating Th17.1 cells in melanoma patients prior to receiving anti-programmed cell death-1 antibody therapy and the onset of sarcoidosis

Circulating Th17.1 Cells in Melanoma Tied to Sarcoidosis

0
Elevation in Th17.1 cells prior to administration of PD-1 checkpoint tx, onset of symptomatic sarcoidosis
Both electronic cigarettes and traditional cigarettes are tied to an increased risk for bladder cancer

AUA: E-Cigarettes Can Also Cause DNA Damage to Bladder Mucosa

0
'Vaping' could lead to cancerous changes in urothelial cells, research indicates
For breast cancer survivors

Tai Chi Can Help Relieve Insomnia in Breast Cancer Survivors

0
Study found it as effective as CBT for improving sleep and depression
Hackers are increasingly targeting hospitals

Hospitals Need to Be Prepared for Ransomware Attacks

0
Medical information a vulnerable target for those planning ransomware attacks, doctor warns
For patients with ovarian cancer

New VTE Often Occurs During Chemo in Ovarian Cancer

0
Most cases of venous thromboembolism occurred during neoadjuvant or adjuvant chemotherapy
Medicaid patients have slightly longer waits at medical appointments than those with private insurance

Outpatient Wait Times Are Longer for Medicaid Recipients

0
Researchers suggest lag time might be due to providers having larger caseloads
An underlying mechanism has been identified that could eventually lead to the first drug therapy for lymphedema

Leukotriene B4 Is Promising Drug Target for Tx of Lymphedema

0
Ketoprofen prevents tissue injury, fluid build-up by blocking leukotriene B4, researchers say
High-price practices have higher scores on certain measures of care coordination and management

Practice Prices Linked to Some Measures of Care Coordination

0
But no differences in overall care ratings, receipt of preventive services, acute care use
The addition of selumetinib to docetaxel does not improve progression-free survival among patients with previously treated advanced KRAS-mutant non-small-cell lung cancer

Adding Selumetinib to Docetaxel Doesn’t Up PFS in NSCLC

0
No improvement in progression-free survival for previously treated advanced KRAS-mutant NSCLC
From 2001 to 2010

Postmarket Safety Events for 32 Percent of Novel Therapeutics

0
Thirty-two percent of 222 FDA approved novel therapeutics from 2001 to 2010 were affected